Protective effect of filgotinib in rat endotoxin-induced uveitis model

Basit Öğe Kaydı
dc.authorid0000-0003-4468-3985en_US
dc.authorid0000-0001-8857-994Xen_US
dc.authorid0000-0003-1337-459Xen_US
dc.authorid0000-0002-0208-8929en_US
dc.authorid0000-0003-2160-7453en_US
dc.contributor.authorErdağ, Murat
dc.contributor.authorBalbaba, Mehmet
dc.contributor.authorİlhan, Nevin
dc.contributor.authorÇalık, İlknur
dc.contributor.authorUlaş, Fatih
dc.date.accessioned2023-06-16T08:03:33Z
dc.date.available2023-06-16T08:03:33Z
dc.date.issued2021en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionFinancial support was received from Firat University Scientific Research Project Center (FUBAP) for this submission (Project No: TF: 2019/197).en_US
dc.description.abstractPurpose To investigate the protective effect of filgotinib in endotoxin-induced uveitis model in rats. Materials and method This study used 24 Wistar Albino rats. Group I (control group) included the healthy controls; in Group II (sham group), only 300 mu g/kg intraperitoneal (ip) lipopolysaccharide (LPS) was administered; and in Group III (treatment group), 3 mg/kg/day filgotinib was administered orally for 10 days followed by 300 mu g/kg ip LPS. In all groups, clinical activity scores were evaluated after 24 h. Moreover, histopathological and immunological examinations were performed. Results In Groups I, II, and III, the mean clinical activity and histopathological examination scores were 0.00, 3.25 +/- 0.70, and 1.89 +/- 0.60 and 0.00, 2.88 +/- 1.12, and 1.44 +/- 0.52, respectively. The clinical activity and histopathological examination scores were significantly increased in the sham group compared to the control group (p < 0.05); these findings were significantly reduced in the treatment group (p < 0.05). The mean TNF-alpha and IL-6 ELISA levels in all groups were 50.20 +/- 3.24, 59.87 +/- 2.98, and 54.34 +/- 4.62 and 30.88 +/- 1.79, 36.77 +/- 1.21, and 33.66 +/- 1.86, respectively. The TNF-alpha and IL-6 ELISA levels were significantly decreased in the treatment group compared to the sham group (p < 0.05); there was no significant difference between the treatment group and the control group (p = 0.105, p = 0.067, respectively) Conclusion Filgotinib may be an alternative treatment option in preventing the development of noninfectious uveitis.en_US
dc.identifier.citationErdağ, M., Balbaba, M., İlhan, N., Çalık, İ., Ulaş, F., Eröksüz, Y., & Yıldırım, H. (2021). Protective effect of filgotinib in rat endotoxin-induced uveitis model. International Ophthalmology, 41, 2905-2912.en_US
dc.identifier.doi10.1007/s10792-021-01851-9
dc.identifier.endpage2912en_US
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.issue8en_US
dc.identifier.pmid33864579en_US
dc.identifier.scopus2-s2.0-85104866660en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2905en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s10792-021-01851-9
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11129
dc.identifier.volume41en_US
dc.identifier.wosWOS:000640858300003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUlaş, Fatih
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofInternational Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFilgotiniben_US
dc.subjectTumor Necrosis Factoren_US
dc.subjectInterleukin-6en_US
dc.subjectUveitisen_US
dc.subjectActive Rheumatoid-Arthritisen_US
dc.subjectSelective Inhibitoren_US
dc.titleProtective effect of filgotinib in rat endotoxin-induced uveitis modelen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
murat-erdag.pdf
Boyut:
565.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu